Kan Zhang1, Dan Cheng1, Lingling Yi1, Huimin Shi1, Guohua Zhen1. 1. Department of Respiratory and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan, China ; Key Laboratory of Respiratory Diseases, National Health and Family Planning Commission of the People's Republic of China Wuhan, China.
Abstract
BACKGROUND: Angiotensin I-converting enzyme (ACE) gene plays an important role in the pathogenesis of cancers. The association between ACE insertion/deletion (I/D) polymorphism and the risk of various cancers has been studied. However, the results of these studies remain conflicting. Therefore, we performed a meta-analysis to evaluate the association between ACE I/D polymorphism and the risk of cancers. METHODS: PubMed, Embase, ScienceDirect, Springer, CNKI, Wanfang, Weipu, CBM databases and Google Scholar were searched for case-control studies on ACE I/D polymorphism and the risk of cancers, published up to Dec 31, 2013. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of the association between ACE I/D polymorphism and cancer risk. RESULTS: Thirty-five published studies with 5007 cases and 8173 controls were included. Overall, there were no significant association between ACE I/D polymorphism and the risk of cancers (II vs. ID+DD OR = 1.05, 95% CI = 0.89-1.23, I vs. D OR = 1.00, 95% CI = 0.89-1.13). However, when stratified by ethnicity, we found a significant association between this polymorphism and cancer risk in Caucasians (II vs. ID+DD: OR = 1.43, 95% CI = 1.02-2.00, I vs. D: OR = 1.23, 95% CI 1.01-1.49). CONCLUSION: ACE I/D polymorphism is associated with the cancer risk in Caucasians.
BACKGROUND:Angiotensin I-converting enzyme (ACE) gene plays an important role in the pathogenesis of cancers. The association between ACE insertion/deletion (I/D) polymorphism and the risk of various cancers has been studied. However, the results of these studies remain conflicting. Therefore, we performed a meta-analysis to evaluate the association between ACE I/D polymorphism and the risk of cancers. METHODS: PubMed, Embase, ScienceDirect, Springer, CNKI, Wanfang, Weipu, CBM databases and Google Scholar were searched for case-control studies on ACE I/D polymorphism and the risk of cancers, published up to Dec 31, 2013. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of the association between ACE I/D polymorphism and cancer risk. RESULTS: Thirty-five published studies with 5007 cases and 8173 controls were included. Overall, there were no significant association between ACE I/D polymorphism and the risk of cancers (II vs. ID+DD OR = 1.05, 95% CI = 0.89-1.23, I vs. D OR = 1.00, 95% CI = 0.89-1.13). However, when stratified by ethnicity, we found a significant association between this polymorphism and cancer risk in Caucasians (II vs. ID+DD: OR = 1.43, 95% CI = 1.02-2.00, I vs. D: OR = 1.23, 95% CI 1.01-1.49). CONCLUSION:ACE I/D polymorphism is associated with the cancer risk in Caucasians.
Entities:
Keywords:
ACE I/D; cancer risk; meta-analysis; single nucleotide polymorphism
Authors: Christoph Röcken; Uwe Lendeckel; Jutta Dierkes; Sabine Westphal; Stacy Carl-McGrath; Brigitte Peters; Sabine Krüger; Peter Malfertheiner; Albert Roessner; Matthias P A Ebert Journal: Clin Cancer Res Date: 2005-04-01 Impact factor: 12.531
Authors: Yong-Gang Zhang; Jin Huang; Jie Zhang; Xiao-Bo Li; Chao He; Yu-Ling Xiao; Can Tian; Hua Wan; Yu-Liang Zhao; Yangzom-Ghising Tsewang; Hong Fan Journal: Arch Med Res Date: 2010-01 Impact factor: 2.235
Authors: Juozas Kupcinskas; Thomas Wex; Jan Bornschein; Michael Selgrad; Marcis Leja; Elona Juozaityte; Gediminas Kiudelis; Laimas Jonaitis; Peter Malfertheiner Journal: BMC Med Genet Date: 2011-08-24 Impact factor: 2.103
Authors: Danial Mehranfard; Gabriela Perez; Andres Rodriguez; Julia M Ladna; Christopher T Neagra; Benjamin Goldstein; Timothy Carroll; Alice Tran; Malav Trivedi; Robert C Speth Journal: J Renin Angiotensin Aldosterone Syst Date: 2021-07-05 Impact factor: 1.636
Authors: Asmahan A El Ezzi; Jordan M Clawson; Mohammed A El-Saidi; Wissam R Zaidan; Abigail Kovash; Jeremy Orellana; AnnaKarina Thornock; Ruhul H Kuddus Journal: Prostate Cancer Date: 2020-02-07